Evidence map›Paper›PMID 38383390›Full record

SynthesisBMC cancer2024

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.

Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Matheus Pedrotti Chavez, Rafael Oliva Morgado Ferreira, Tiago Biachi De Castria, Rommel Mario Rodríguez Burbano

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 6 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 6 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Gastric cancer burden and regional disparities among Helicobacter pylori-positive patients in the Americas: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Francisco Cezar Aquino de MoraesFederal University of Pará, 66073-005, Belém, Pará, Brazil. francisco.cezar2205@gmail.com.ORCID http://orcid.org/0000-0003-0623-8135
Eric PasqualottoFederal University of Santa Catarina, 88040-900, Florianópolis, Santa Catarina, Brazil.ORCID https://orcid.org/0000-0002-6484-1162
Matheus Pedrotti ChavezFederal University of Santa Catarina, 88040-900, Florianópolis, Santa Catarina, Brazil.ORCID https://orcid.org/0009-0009-9278-6795
Rafael Oliva Morgado FerreiraFederal University of Santa Catarina, 88040-900, Florianópolis, Santa Catarina, Brazil.ORCID https://orcid.org/0000-0002-3203-0509
Tiago Biachi De CastriaMoffitt Cancer Center, 12902 USF Magnolia Drive, 33612, Tampa, FL, USA.ORCID https://orcid.org/0000-0001-6832-2485
Rommel Mario Rodríguez BurbanoOphir Loyola Hospital, 66063-240, Belém, Pará, Brazil.ORCID http://orcid.org/0000-0002-4872-234X
Universidade Federal de Santa Catarina · BRInstituto Federal de Educação, Ciência e Tecnologia do Pará · BRUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)-positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJ) is not yet fully elucidated.

methodsWe searched PubMed, Embase and Cochrane databases for randomized controlled trials (RCTs) that investigated Zolbetuximab plus chemotherapy versus chemotherapy alone for GC or GEJ adenocarcinoma. We computed hazard-ratios (HRs) or odds-ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs).

resultsThree studies and 1,233 patients were included. Comparing with Zolbetuximab plus chemotherapy versus chemotherapy alone, progression-free survival (PFS) rate (HR 0.64; 95% CI 0.49-0.84; p < 0.01) and overall survival (OS) rate (HR 0.72; 95% CI 0.62-0.83; p < 0.01) were significant in favor of the Zolbetuximab group. Regarding effectiveness, the Objective Response Rate (ORR) was (OR 1.15; 95% CI 0.87-1.53; p = 0.34).

conclusionsIn this comprehensive systematic review and meta-analysis of RCTs, the incorporation of Zolbetuximab alongside chemotherapy offers a promising prospect for reshaping the established treatment paradigms for patients diagnosed with advanced CLDN18.2-positive GC/GEJ cancer.

Indexed as

AdenocarcinomaEsophageal NeoplasmsStomach NeoplasmsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsClaudinsEsophagogastric JunctionHumansRandomized Controlled Trials as TopicAntibodies, MonoclonalClaudinsCLDN18 protein, humanzolbetuximabAdenocarcinoma of the gastro-oesophageal junctionClaudin-18 isoform 2Gastric adenocarcinomaOesophageal adenocarcinomaZolbetuximab

Identifiers

PMID38383390
PMCPMC10882870
OpenAlexW4392004377

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.